Andre Strydom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3593897/publications.pdf

Version: 2024-02-01

153 6,734 45 73
papers citations h-index g-index

192 192 192 5683
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Psychiatric issues in aging and dementia. , 2022, , 273-288.		O
2	Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. Journal of Neurodevelopmental Disorders, 2022, 14, 22.	1.5	13
3	COVID-19 Vaccination of Individuals with Down Syndromeâ€"Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines, 2022, 10, 530.	2.1	8
4	Susceptibility to COVID-19 Diagnosis in People with Down Syndrome Compared to the General Population: Matched-Cohort Study Using Primary Care Electronic Records in the UK. Journal of General Internal Medicine, 2022, 37, 2009-2015.	1.3	8
5	Estimation of the minimal clinically important difference on the Aberrant Behaviour Checklist–Irritability (ABC-I) for people with intellectual disabilities who display aggressive challenging behaviour: A triangulated approach. Research in Developmental Disabilities, 2022, 124, 104202.	1.2	6
6	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63
7	Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome. Alzheimer's and Dementia, 2021, 17, 595-604.	0.4	16
8	Genetic dissection of down syndrome-associated alterations in APP/amyloid- \hat{l}^2 biology using mouse models. Scientific Reports, 2021, 11, 5736.	1.6	10
9	The COVID-19 pandemic should be last orders for poor care of people with neurodevelopmental disorders. British Journal of Psychiatry, 2021, 218, 302-304.	1.7	5
10	Medical vulnerability of individuals with Down syndrome to severe COVID-19–data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine, 2021, 33, 100769.	3.2	73
11	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. NeuroMolecular Medicine, 2021, 23, 561-571.	1.8	30
12	The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 1882.	1.0	14
13	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. Frontiers in Immunology, 2021, 12, 621440.	2.2	26
14	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
15	The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population. Scientific Reports, 2021, 11, 13438.	1.6	6
16	Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3748.	1.0	7
17	Blood Biomarkers for Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3639.	1.0	17
18	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1. Frontiers in Psychiatry, 2021, 12, 701729.	1.3	7

#	Article	IF	CITATIONS
19	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	4.9	29
20	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. Molecular Syndromology, 2021, 12, 202-218.	0.3	6
21	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12184.	1.2	10
22	Comparison of resting-state EEG between adults with Down syndrome and typically developing controls. Journal of Neurodevelopmental Disorders, 2021, 13, 48.	1.5	8
23	Understanding inequalities in COVID-19 outcomes following hospital admission for people with intellectual disability compared to the general population: a matched cohort study in the UK. BMJ Open, 2021, 11, e052482.	0.8	29
24	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. Journal of Clinical Medicine, 2021, 10, 4582.	1.0	9
25	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. Journal of Clinical Medicine, 2021, 10, 5125.	1.0	24
26	Diagnosis of Attention Deficit Hyperactivity Disorder in Intellectual Disability: Diagnostic and Statistical Manual of Mental Disorder V versus clinical impression. Journal of Intellectual Disability Research, 2020, 64, 251-257.	1.2	8
27	Cognitive and clinical outcome measures for Alzheimer's disease prevention trials in adults with Down syndrome. Alzheimer's and Dementia, 2020, 16, e043478.	0.4	0
28	Differential Associations of Apolipoprotein E $\hat{l}\mu 4$ Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome. JAMA Network Open, 2020, 3, e2018221.	2.8	7
29	Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's and Dementia, 2020, 16, 1065-1077.	0.4	52
30	Dynamics of plasma biomarkers in Down syndrome: the relative levels of \hat{Al}^2 42 decrease with age, whereas NT1 tau and NfL increase. Alzheimer's Research and Therapy, 2020, 12, 27.	3.0	20
31	Down syndrome. Nature Reviews Disease Primers, 2020, 6, 9.	18.1	376
32	Staff training in positive behaviour support for behaviour that challenges in people with intellectual disability: cost-utility analysis of a cluster randomised controlled trial. BJPsych Open, 2020, 6, e15.	0.3	5
33	Health comorbidities and cognitive abilities across the lifespan in Down syndrome. Journal of Neurodevelopmental Disorders, 2020, 12, 4.	1.5	85
34	Clinical and cost effectiveness of staff training in the delivery of Positive Behaviour Support (PBS) for adults with intellectual disabilities, autism spectrum disorder and challenging behaviour - randomised trial. BMC Psychiatry, 2020, 20, 161.	1.1	9
35	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12062.	1.2	12
36	Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and metaâ€analyses. Developmental Neurobiology, 2019, 79, 684-698.	1.5	18

#	Article	IF	CITATIONS
37	Process evaluation of a randomised controlled trial of PBS-based staff training for challenging behaviour in adults with intellectual disability. PLoS ONE, 2019, 14, e0221507.	1.1	20
38	Reply to "Down Syndrome Cognitive Marker's Significance in Alzheimer's Disease and Dementia Management― Alzheimer's and Dementia, 2019, 15, 1238-1239.	0.4	0
39	Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review. Journal of Neurodevelopmental Disorders, 2019, 11, 20.	1.5	26
40	Resource use and cost of annual health checks in primary care for people with intellectual disabilities. Journal of Intellectual Disability Research, 2019, 63, 233-243.	1.2	5
41	Comparison of Receptive Verbal Abilities Assessed Using the KBIT-2 and BPVS3 in Adults With Down Syndrome. Frontiers in Psychology, 2019, 9, 2730.	1.1	6
42	Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome. Frontiers in Psychiatry, 2019, 10, 158.	1.3	18
43	Optimising psychotropic medication prescribing to reduce adverse drug events. Journal of Intellectual Disability Research, 2019, 63, 369-371.	1.2	0
44	Dynamic Causal Modeling of the Relationship between Cognition and Theta–alpha Oscillations in Adults with Down Syndrome. Cerebral Cortex, 2019, 29, 2279-2290.	1.6	20
45	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 26.	3.0	56
46	Genetics of Intellectual Disability. , 2019, , 12-27.		1
46		0.8	1 14
	Genetics of Intellectual Disability. , 2019, , 12-27. Experiences of psychotropic medication use and decision-making for adults with intellectual	0.8	
47	Genetics of Intellectual Disability., 2019, , 12-27. Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK. BMJ Open, 2019, 9, e032861. A structured medication review tool to promote psychotropic medication optimisation for adults		14
47	Genetics of Intellectual Disability., 2019,, 12-27. Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK. BMJ Open, 2019, 9, e032861. A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study. BMJ Open, 2019, 9, e033827. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and	0.8	3
48	Genetics of Intellectual Disability., 2019, , 12-27. Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK. BMJ Open, 2019, 9, e032861. A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study. BMJ Open, 2019, 9, e033827. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312. Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years.	0.8	14 3 310
47 48 49 50	Cenetics of Intellectual Disability., 2019, , 12-27. Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK. BMJ Open, 2019, 9, e032861. A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study. BMJ Open, 2019, 9, e033827. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312. Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurology, 2019, 76, 152. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's	0.8 0.4 4.5	14 3 310 110
47 48 49 50	Cenetics of Intellectual Disability., 2019, , 12-27. Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK. BMJ Open, 2019, 9, e032861. A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study. BMJ Open, 2019, 9, e033827. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312. Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurology, 2019, 76, 152. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's and Dementia, 2019, 15, 245-257.	0.8 0.4 4.5	14 3 310 110 68

#	Article	IF	CITATIONS
55	Clinical outcomes of staff training in positive behaviour support to reduce challenging behaviour in adults with intellectual disability: cluster randomised controlled trial. British Journal of Psychiatry, 2018, 212, 161-168.	1.7	61
56	Neurodevelopmental risk copy number variants in adults with intellectual disabilities and comorbid psychiatric disorders. British Journal of Psychiatry, 2018, 212, 287-294.	1.7	30
57	Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free Radical Biology and Medicine, 2018, 114, 3-9.	1.3	61
58	Consensus statement of the international summit on intellectual disability and Dementia related to post-diagnostic support. Aging and Mental Health, 2018, 22, 1406-1415.	1.5	18
59	Genetic testing in intellectual disability psychiatry: Opinions and practices of <scp>UK</scp> child and intellectual disability psychiatrists. Journal of Applied Research in Intellectual Disabilities, 2018, 31, 273-284.	1.3	16
60	Assessing Autism in Adults: An Evaluation of the Developmental, Dimensional and Diagnostic Interview—Adult Version (3Di-Adult). Journal of Autism and Developmental Disorders, 2018, 48, 549-560.	1.7	21
61	Author's reply to: Difficulties of diagnosing and managing dementia in people with Down syndrome. British Journal of Psychiatry, 2018, 213, 669-669.	1.7	0
62	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 703-713.	1.8	63
63	Association of Focused Medication Review With Optimization of Psychotropic Drug Prescribing. JAMA Network Open, 2018, 1, e183750.	2.8	19
64	Author's reply. British Journal of Psychiatry, 2018, 213, 667-668.	1.7	0
65	Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. Acta Neuropathologica, 2018, 136, 569-587.	3.9	47
66	Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 741-751.	1.7	64
67	Trisomy of human chromosome 21 enhances amyloid- \hat{l}^2 deposition independently of an extra copy of <i> APP </i> . Brain, 2018, 141, 2457-2474.	3.7	96
68	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Journal of Alzheimer's Disease, 2018, 63, 797-819.	1.2	38
69	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimer's Research and Therapy, 2018, 10, 39.	3.0	43
70	Positive behaviour support training for staff for treating challenging behaviour in people with intellectual disabilities: a cluster RCT. Health Technology Assessment, 2018, 22, 1-110.	1.3	20
71	New horizons for mental health research in intellectual disabilities. Journal of Intellectual Disability Research, 2017, 61, 519-520.	1.2	0
72	Cognitive decline and dementia in Down syndrome. Current Opinion in Psychiatry, 2017, 30, 102-107.	3.1	54

#	Article	IF	CITATIONS
73	Psychotropic prescribing in people with intellectual disability and challenging behaviour. BMJ: British Medical Journal, 2017, 358, j3896.	2.4	19
74	Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open, 2017, 7, e017406.	0.8	63
75	Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity. Neuroscience Letters, 2017, 636, 254-257.	1.0	20
76	Chromosomal microarray testing in adults with intellectual disability presenting with comorbid psychiatric disorders. European Journal of Human Genetics, 2017, 25, 66-72.	1.4	30
77	Predictors of Age of Diagnosis and Survival of Alzheimer's Disease in Down Syndrome. Journal of Alzheimer's Disease, 2017, 61, 717-728.	1.2	94
78	The Relationship Between Sound–Shape Matching and Cognitive Ability in Adults With Down Syndrome. Multisensory Research, 2017, 30, 537-547.	0.6	1
79	Donation of peripheral blood stem cells to unrelated strangers: A thematic analysis. PLoS ONE, 2017, 12, e0186438.	1.1	5
80	Intracerebral haemorrhage in Down syndrome: protected or predisposed?. F1000Research, 2016, 5, 876.	0.8	30
81	The importance of understanding individual differences in Down syndrome. F1000Research, 2016, 5, 389.	0.8	151
82	Assessing Specific Cognitive Deficits Associated with Dementia in Older Adults with Down Syndrome: Use and Validity of the Arizona Cognitive Test Battery (ACTB). PLoS ONE, 2016, 11, e0153917.	1.1	33
83	Developing an Informant Questionnaire for Cognitive Abilities in Down Syndrome: The Cognitive Scale for Down Syndrome (CS-DS). PLoS ONE, 2016, 11, e0154596.	1.1	27
84	From <i>DSM</i> to <i>DM-ID</i> . Journal of Mental Health Research in Intellectual Disabilities, 2016, 9, 189-204.	1.3	23
85	Best practice in caring for adults with dementia and learning disabilities. Nursing Standard (Royal) Tj ETQq $1\ 1\ 0$.784314 rg 0.1	gBT_/Overlock
86	Alzheimer's disease in older individuals with Down syndrome. European Neuropsychopharmacology, 2016, 26, S113-S114.	0.3	0
87	Self-reported stigma and its association with socio-demographic factors and physical disability in people with intellectual disabilities: results from a cross-sectional study in England. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 465-474.	1.6	30
88	Behavioural and psychological symptoms of dementia in Down syndrome: European development of the novel BPSD-DS evaluation scale. European Neuropsychopharmacology, 2016, 26, S641.	0.3	0
89	Prisoners with intellectual disabilities and detention status. Findings from a UK cross sectional study of prisons. Research in Developmental Disabilities, 2016, 53-54, 189-197.	1.2	12
90	The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. Wellcome Open Research, 2016, $1,11.$	0.9	55

#	Article	IF	Citations
91	Behavioural phenotypes in translation. Journal of Intellectual Disability Research, 2015, 59, 785-786.	1.2	1
92	Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 350-356.	2.0	11
93	Dementia diagnostic criteria in Down syndrome. International Journal of Geriatric Psychiatry, 2015, 30, 857-863.	1.3	77
94	Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Adults with Intellectual Disability. Drugs and Aging, 2015, 32, 95-102.	1.3	30
95	A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nature Reviews Neuroscience, 2015, 16, 564-574.	4.9	404
96	Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ, The, 2015, 351, h4326.	3.0	244
97	Ethnicity and selfâ€reported experiences of stigma in adults with intellectual disability in <scp>C</scp> ape <scp>T</scp> own, <scp>S</scp> outh <scp>A</scp> frica. Journal of Intellectual Disability Research, 2015, 59, 530-540.	1.2	16
98	Behavioural and psychological symptoms ofÂdementia in Down syndrome: Early indicators ofÂclinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	1.1	201
99	Self-reported stigma and symptoms of anxiety and depression in people with intellectual disabilities: Findings from a cross sectional study in England. Journal of Affective Disorders, 2015, 187, 224-231.	2.0	54
100	Memory Decline in Down Syndrome and Its Relationship to iPF2alpha, a Urinary Marker of Oxidative Stress. PLoS ONE, 2014, 9, e97709.	1.1	17
101	Does rare matter? Copy number variants at 16p11.2 and the risk of psychosis: A systematic review of literature and meta-analysis. Schizophrenia Research, 2014, 159, 340-346.	1.1	27
102	Use of medication for challenging behaviour in people with intellectual disability. British Journal of Psychiatry, 2014, 205, 6-7.	1.7	30
103	Estimated verbal IQ and the odds of problem gambling: a population-based study. Psychological Medicine, 2014, 44, 1739-1749.	2.7	15
104	Clinical and cost effectiveness of staff training in Positive Behaviour Support (PBS) for treating challenging behaviour in adults with intellectual disability: a cluster randomised controlled trial. BMC Psychiatry, 2014, 14, 219.	1.1	36
105	Carer-led health interventions to monitor, promote and improve the health of adults with intellectual disabilities in the community: A systematic review. Research in Developmental Disabilities, 2014, 35, 887-907.	1.2	26
106	Standardised patients with intellectual disabilities in training tomorrow's doctors. Psychiatric Bulletin (2014), 2014, 38, 132-136.	0.4	32
107	Assessment of an incentivised scheme to provide annual health checks in primary care for adults with intellectual disability: a longitudinal cohort study. Lancet Psychiatry, the, 2014, 1, 522-530.	3.7	58
108	Behavioral Phenotypes and Genetic Syndromes. Autism and Child Psychopathology Series, 2014, , 109-122.	0.1	1

#	Article	IF	CITATIONS
109	Validity of Criteria for Dementia in Older People With Intellectual Disability. American Journal of Geriatric Psychiatry, 2013, 21, 279-288.	0.6	19
110	Manualised Individual Cognitive Behavioural Therapy for mood disorders in people with mild to moderate intellectual disability: A feasibility randomised controlled trial. Journal of Affective Disorders, 2013, 151, 186-195.	2.0	59
111	Incidence of dementia in older adults with intellectual disabilities. Research in Developmental Disabilities, 2013, 34, 1881-1885.	1.2	105
112	The relationship between happiness and intelligent quotient: the contribution of socio-economic and clinical factors. Psychological Medicine, 2013, 43, 1303-1312.	2.7	47
113	Evaluation of medical students' attitudes towards people with intellectual disabilities: a naturalistic study in one medical school. Advances in Mental Health and Intellectual Disabilities, 2013, 7, 18-26.	0.7	18
114	Discrimination and Other Barriers to Accessing Health Care: Perspectives of Patients with Mild and Moderate Intellectual Disability and Their Carers. PLoS ONE, 2013, 8, e70855.	1.1	203
115	Improving Alzheimer's disease outcomes in Down's syndrome. Lancet, The, 2012, 379, 498-500.	6.3	7
116	Self stigma in people with intellectual disabilities and courtesy stigma in family carers: A systematic review. Research in Developmental Disabilities, 2012, 33, 2122-2140.	1.2	237
117	Oxidative Stress and Memory Decline in Adults with Down Syndrome: Longitudinal Study. Journal of Alzheimer's Disease, 2012, 31, 277-283.	1.2	42
118	Older adults with intellectual disability. Current Opinion in Psychiatry, 2012, 25, 359-364.	3.1	68
119	Crossâ€Cultural Validation of a Measure of Felt Stigma in People with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2012, 25, 11-19.	1.3	14
120	Validity of Criteria for Dementia in Older People With Intellectual Disability. American Journal of Geriatric Psychiatry, $2012, 1.$	0.6	1
121	Psychiatric morbidity in prisoners with intellectual disabilities: analysis of prison survey data for England and Wales. British Journal of Psychiatry, 2011, 199, 156-157.	1.7	62
122	Cognitive behaviour therapy (CBT) for anxiety and depression in adults with mild intellectual disabilities (ID): a pilot randomised controlled trial. Trials, 2011, 12, 95.	0.7	33
123	Insight and other predictors of physical examination refusal in psychotic illness. Journal of Mental Health, 2011, 20, 319-327.	1.0	2
124	Service use and cost of mental disorder in older adults with intellectual disability. British Journal of Psychiatry, 2010, 196, 133-138.	1.7	48
125	Caregiving and Adults With Intellectual Disabilities Affected by Dementia. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 26-33.	1.7	28
126	Reliance on Carer Reports of Early Symptoms of Dementia Among Adults With Intellectual Disabilities. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 34-41.	1.7	17

#	Article	IF	CITATIONS
127	Major Health Risks in Aging Persons With Intellectual Disabilities: An Overview of Recent Studies. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 59-69.	1.7	165
128	Aging in Down Syndrome: Morbidity and Mortality. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 70-81.	1.7	85
129	Dementia in Older Adults With Intellectual Disabilities-Epidemiology, Presentation, and Diagnosis. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 96-110.	1.7	110
130	Use of the HoNOS–LD in identifying domains of change. The Psychiatrist, 2010, 34, 322-326.	0.3	14
131	Intellectual disability across cultures. Psychiatry (Abingdon, England), 2009, 8, 355-357.	0.2	12
132	Behavioural phenotypes and mental disorders. Psychiatry (Abingdon, England), 2009, 8, 391-397.	0.2	3
133	Oxidative stress and cognitive ability in adults with Down syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 76-80.	2.5	52
134	The relationship of dementia prevalence in older adults with intellectual disability (ID) to age and severity of ID. Psychological Medicine, 2009, 39, 13-21.	2.7	78
135	Psychiatric morbidity and social functioning among adults with borderline intelligence living in private households. Journal of Intellectual Disability Research, 2008, 52, 95-106.	1.2	100
136	What to tell and how to tell: a qualitative study of information sharing in research for adults with intellectual disability. Journal of Medical Ethics, 2008, 34, 501-506.	1.0	19
137	A measure of perceived stigma in people with intellectual disability. British Journal of Psychiatry, 2008, 193, 410-415.	1.7	51
138	Prevalence of dementia in intellectual disability using different diagnostic criteria. British Journal of Psychiatry, 2007, 191, 150-157.	1.7	134
139	Mental Health and Social Care Needs of Older People with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2005, 18, 229-235.	1.3	40
140	Social outcomes in adulthood of children with intellectual impairment: evidence from a birth cohort. Journal of Intellectual Disability Research, 2005, 49, 171-182.	1.2	55
141	Letter to the editor. Journal of Intellectual Disability Research, 2004, 48, 769-770.	1.2	2
142	Are dedicated research posts of value to psychiatry trainees?. Psychiatric Bulletin, 2004, 28, 260-263.	0.3	7
143	About leaving: making sense of moving on. British Journal of Learning Disabilities, 2003, 31, 70-73.	0.8	2
144	A memory clinic for older people with intellectual disabilities. Aging and Mental Health, 2003, 7, 418-423.	1.5	24

#	Article	IF	CITATIONS
145	Down's syndrome. Lancet, The, 2003, 362, 80-81.	6.3	4
146	Diagnostic instruments for dementia in older people with intellectual disability in clinical practice. Aging and Mental Health, 2003, 7, 431-437.	1.5	71
147	Mental disorders predicted all cause and cause specific deaths in Finnish adults. Evidence-Based Mental Health, 2002, 5, 93-93.	2.2	0
148	Clinical use of structural magnetic resonance imaging in the diagnosis of dementia in adults with Down's syndrome. Irish Journal of Psychological Medicine, 2002, 19, 60-63.	0.7	41
149	Self-help resources for adults with a learning disability. Psychiatric Bulletin, 2001, 25, 495-496.	0.3	0
150	Long-term affective disorder in people with mild learning disability. British Journal of Psychiatry, 2001, 179, 523-527.	1.7	110
151	Patient information leaflets for people with learning disabilities who take psychiatric medication. British Journal of Learning Disabilities, 2001, 29, 72-76.	0.8	23
152	Randomized trial of psychotropic medication information leaflets for people with intellectual disability. Journal of Intellectual Disability Research, 2001, 45, 146-151.	1.2	24
153	Mental Health of Older People. , 0, , 149-168.		0